Skip to main content
Timothy Kuzel, MD, Oncology, Orland Park, IL

TimothyKuzelMDFACP

Oncology Orland Park, IL

Cutaneous Lymphoma, Genitourinary Oncology, Hematologic Oncology, Melanoma

Clinical Professor of Medicine Northwestern University Distinguished Physician, St George corp Associate Director Clinical Research Network, Robert H Lurie Comprehensive Cancer Center Northwestern University Oncology Service Line Lead, South Region

Dr. Kuzel is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

See Dr. Kuzel's full profile

Already have an account?

  • Office

    15300 West Ave
    Robert H Lurie Comp Ca Ctr
    Orland Park, IL 60462
    Phone+1 708-226-2513
    Fax+1 312-942-3192

Summary

  • I am the Samuel G Taylor III Professor of Oncology, and the Chief of the Division of Hematology/Oncology and Cell Therapy at Rush University since June 2016. Prior to that I spent 26 years as a Professor of Medicine and Dermatology in the Division of Hematology/Oncology at Northwestern University, Feinberg School of Medicine. I have focused my career on the design and execution of clinical trials with a specific focus on experimental therapeutics, especially phase I and phase II therapeutics rationally designed to exploit molecular and/or protein alterations within tumor cells and immunotherapeutic approaches/agents. Agents utilized have included chemotherapy drugs, targeted agents, cytokines, vaccines, and other novel immunotherapeutics. I have been a Co-PI on a SPORE in Prostate Cancer at Northwestern focused on immunomodulation to reverse resistance to oral novel anti-androgen therapies (the grant is in NCE thru Aug 2021). I have also had Prostate Cancer Foundation and NIH funding for translational agent development. I also worked in the area of shared decision making and identification of adverse events associated with drug therapy of cancer. I have served on a number of NCI site visit teams as a reviewer for Program Projects for 1) Immunotherapy in renal cell Ca, 2) Melanoma with dendritic cell-based immunotherapy approaches, and 3) Cellular immunotherapy, as well as 4) Community based NCI centers (NCOROP), and Novel Statistical Clinical Programs. In addition, I participated on several NCCN guidelines committees including Kidney/Testis and Bladder and Prostate at various times. I serve on multiple Data Monitoring Committees of phase II and III global check point inhibitor clinical trials.

Education & Training

  • McGaw Medical Center of Northwestern University
    McGaw Medical Center of Northwestern UniversityFellowship, Hematology and Medical Oncology, 1987 - 1990
  • McGaw Medical Center of Northwestern University
    McGaw Medical Center of Northwestern UniversityResidency, Internal Medicine, 1984 - 1987
  • University of Michigan Medical School
    University of Michigan Medical SchoolClass of 1984
  • University of Michigan
    University of MichiganBA, Biomedical Sciences, Cum Laude, 1978 - 1981
  • University of Michigan
    University of MichiganB.S., Biomedical Sciences, 1981

Certifications & Licensure

  • IL State Medical License
    IL State Medical License 1984 - 2026
  • American Board of Internal Medicine Internal Medicine
  • American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

  • Chicago Magazine: Top Doctors Castle Connolly, 2008, 2010, 2012, 2014, 2016, 2018, 2020
  • America's Top Doctors Castle Connolly, 2008-2017
  • America's Top Doctors for Cancer Castle Connolly, 2007-2017
  • Join now to see all

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • Type 2 Innate Lymphoid Cells Impede IL-33–Mediated Tumor Suppression  
    Timothy M Kuzel, Bin Zhang, The Journal of Immunology
  • The Present and Future Cardiovascular Medicine and Society the Cardiologist and the Cancer Patient: Challenges to Cardio-Oncology (Or Onco-Cardiology) and Call to Action  
    Agne Paner, Hena Patel, Timothy Kuzel, Parameswaran Venugopal, Tochi M Okwuosa, Nicole Prabhu, Kim A Williams, ScienceDirect
  • The efficacy of lenvatanib and everolimus in Chromophobe-type non-Clear Cell Renal Cell Cancer: A case report and Literature review  
    Schwartz C, Pfanzelter N, Kuzel TM, Clin Genitourin Cancer, 1/25/2017
  • Join now to see all

Books/Book Chapters

  • Join now to see all

Abstracts/Posters

  • A Phase 1a/1b Trial of ST-001, a Fenretinide Phospholipid Suspension for 4-Hour Intravenous Infusion in Relapsed/Refractory T-Cell Non-HodgkinÍs Lymphoma
    Timothy M. Kuzel, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
  • Impact of use of Phosphodiesterase Type 5 Inhibitors (PDE5-I) after Radical Prostatectomy (RP) on Biochemical Recurrence-free (BCRF) and Overall Survival (OS): A Retro...
    Arden B. Roston, Irene B. Helenowski, William Catalona, Robin Leikin, Michael Gurley, Luke Trapp, Borko Jovanovic, Timothy M. Kuzel, J Clin Oncol; Proc of GU ASCO, 1/1/2017
  • Analysis of overall survival (OS) based on tumor target lesion change in the phase 3 METEOR trial of cabozantinib (cabo) versus everolimus (eve) in advanced renal cell...
    Sumanta Pal, Robert J Motzer, Mayer Fishman, Raymond McDermott, Jose Passos Coelho, Evgeniy Kopyltsov, Xavier Garcia del Muro Solans, Jesús Garcia Donas, Ramazan Yildi..., J Clin Oncol; Proc of GU ASCO, 1/1/2017
  • Join now to see all

Lectures

  • Updated Analyses of the International, Open-label, Randomized, Phase 3 ALCANZA Study: Longer-term Evidence for Superiority of Brentuximab Vedotin Versus Methotrexate o... 
    London, United Kingdom - 1/13/2017
  • Immunotherapy of Cancer 
    1/1/2012
  • A phase 2 mutli-center, randomized, open-label study of two dose levels of IMO-2055 in Patients with metastatic or recurrent Renal Cell Carcinoma. 
    1/1/2009
  • Join now to see all

Other

  • The use of Gemcitabine in metastatic urothelial transitional cell cancer 
    Kuzel TM and Stadler WM, Lilly Monograph
    1/1/1996
  • Book Review of --Atkins MB and Mier JW. Therapeutic Applications of Interleukin-2. 
    Kuzel TM, Doody's Health Sciences Book Review Annual
    1/1/1993
  • Interferons: Basic Principles and Clinical Applications. 
    Kuzel TM. Book Review of --Estrov Z, Kurzock R, and Talpaz M, Doody's Health Sciences Book Review Annual
    1/1/1993

Press Mentions

  • Combination Treatment Improves Survival in Advanced Prostate Cancer with Genetic Mutations
    Combination Treatment Improves Survival in Advanced Prostate Cancer with Genetic MutationsSeptember 6th, 2024
  • Rush Earns ASCO QOPI Certification for High-Quality Cancer Care
    Rush Earns ASCO QOPI Certification for High-Quality Cancer CareSeptember 5th, 2019
  • Personalized Vaccine Helps Patients Fight Ovarian Cancer
    Personalized Vaccine Helps Patients Fight Ovarian CancerApril 12th, 2018
  • Join now to see all

Professional Memberships